Centro De Ingenieria Genetica Y Biotecnologia

Centro De Ingenieria Genetica Y Biotechnologia

Ehime University

Toko Yakuhin Kogyo Co., Ltd.

Eduardo Penton Arias

Gerardo Enrique Guillen Nieto

Julio Cesar Aguilar Rubido

Alexis Musacchio Lasa

Enrique Iglesias Perez

Maria De Jesus Leal Angulo

Verena Lucila Muzio Gonzalez

Antonieta Herrera Buch

Dagmara Pichardo Diaz

Giselle Penton Rol

Jorge Amador Berlanga Acosta

Taizou Kamishita

Sonia Gonzalez Blanco

Diana Garcia Del Barco Herrera

Tania Carmenate Portilla

Julio César Aguilar Rubido

Danay Cibrian Vera

Jorge Valdes Hernandez

Yadira Lobaina Mato

Pedro Antonio Lopez Saura

Takashi Miyazaki

Osamu Yoshida

Yoichi Hiasa

Viviana Falcon Cama

Mariela Vazquez Castillo

Vladimir Armando Besada Perez

Majel Cervantes Llanos

Fazle Akbar Sheikh Mohammad

Luis Javier Gonzalez Lopez

Jorge Agustin Aguiar Santiago

Juan Joel Madrazo Pi&ntilde;ol

Maylin Diaz Martinez

Maydel Hechavarria Gay

Cirse Mesa Pardillo

Luis Javier Cruz Ricondo

Lissere Crombet Menedez

Carmen Maria Valenzuela Silva

Nancy Pavon Fuentes

Gloria Veliz Rios

Gilberto Lazaro Pardo Andreu

Efrain Rodriguez Jimenez

Javier Marin Prida

Belquis Sandez Oquendo

Alexey Llopiz Arzuaga

Diogenes Quitana Vazquez

Gerardo Enrique Guill Nenieto

Yanet Tambara Hernandez

Iloki Assanga Simon Bernard

Minerva Sewer Mensies

Dina Tleugulova

Freya De Freyre Almeida

Dina Tleugabulova

Verena Lucila Muzio González

The present invention relates to a rhinovaccination system for preventing and treating hepatitis B, comprising a hepatitis B vaccine composition for administration to nasal mucosa in combination with a medical nozzle device.

Hepatitis B vaccine transnasal administration system

The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.

Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases

The present invention consists of the combination of Interferon alpha and C-Phycocyanin (IFN-&#x3b1;/C-Phyco) for obtaining a pharmaceutical preparation for autoimmune disease, allergy and cancer treatments. The anti-inflammatory, immunomodulator, antioxidant, anti-viral, anti-proliferative and anti-tumoral effects, associated to the regulatory T cell inducer effect demonstrated in this invention is the rationale for the use of the IFN-&#x3b1;/C-Phyco combination in these diseases.

Treatment of multiple sclerosis by administration of interferon alpha and C-phycocyanin

The present invention is for a formulation comprising a nucleic acid vaccine and an immunoenhancing amount of acemannan, whereby the acemannan enhances immune response, in a host, to the vaccine. The present invention is also for a method of enhancing the immune response of a host to a nucleic acid vaccine by administering a formulation comprising a nucleic acid vaccine and acemannan.

Formulation of nucleic acid and acemannan

The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of the organism to vaccine antigens in the serum and the mucous lining. With this aim, a formulation was developed that contained as the main components the surface antigen of the hepatitis B virus and the acemannan in adequate proportions. As an extension of this result, formulations were developed in which a) HBsAg was used as the homologous or heterologous antigen carrier b) delivery systems of particulated antigens and c) soluble antigens, combined with the acemannan in specific proportions. The formulations of this invention are applicable in the pharmaceutical industry as vaccine formulations for human and veterinary use.

Immunopotentiating formulations for vaccinal use

Growing community of inventors

Ciudad de la Habana, Cuba

Eduardo Penton Arias